You searched for Financier

- 23 Mars 2026

Ipsen provides clarifications regarding the succession of Mr. Henri Beaufour – Group governance agreement relating to Beech Tree*

PARIS, FRANCE, 23 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that Beech Tree, which holds directly and indirectly 26.03% of the share capital and 33.05% of the voting rights of Ipsen SA, announces that Altawin, Fondation Alasol and B...

- 22 Décembre 2025

Ipsen, Université de Montréal and IRICoR expand long-term partnership to accelerate early-stage oncology innovations

PARIS, FRANCE AND MONTREAL, CANADA 22 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR, of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, announced today a new research coll...

- 09 Janvier 2026

Ipsen Statement on Lanreotide Generic Supply Challenges

Attachment...

- 05 Décembre 2025

Ipsen provides update on legacy of Henri Beaufour

PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representativ...

- 14 Octobre 2025

Ipsen announces the conclusion of an agreement between its main shareholders representing 52.06% of the capital and 66.15% of the voting rights

PARIS, FRANCE, 14 OCTOBER 2025 - Ipsen (Euronext: IPN: ADR: IPSEY) announced today that its Board of Directors has been informed of the conclusion of a new agreement1 between Highrock (controlled by Anne Beaufour), Beech Tree (controlled by Henri Beaufour)...

- 30 Janvier 2026

Ipsen expands pre-clinical pipeline in rare neurodegenerative diseases

PARIS, FRANCE 30 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today a new global collaboration and option agreement with Origami Therapeutics for a research stage protein degrader program targeting genetic neurodegenerative diseases. Followin...

- 13 Mars 2025

Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s

PARIS, FRANCE, March 13th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today it has been assigned long-term credit ratings of Baa3 by Moody’s and BBB- by S&P Global Ratings, both with a “Stable” out...

- 23 Mars 2026

Ipsen apporte des précisions sur la succession de Monsieur Henri Beaufour – Accord de gouvernance du Groupe relatif à Beech Tree*

PARIS, FRANCE, 23 mars 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a été informé que Beech Tree, qui détient directement et indirectement 26,03 % du capital et 33,05 % des droits de vote d'Ipsen SA, annonce la conclusion d'un accord de gouvernance entre A...

- 09 Juin 2026

Ipsen welcomes the European Union’s publication of the Joint Clinical Assessment for Ojemda® (tovorafenib)

PARIS, FRANCE, 9 JUNE 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) today welcomes the publication of the European Union’s (EU) Joint Clinical Assessment (JCA) report for Ojemda® (tovorafenib) for the treatment of patients with relapsed or refractory BRAF-al...